Costs and effects of on-demand treatment of hereditary angioedema in Italy: a prospective cohort study of 167 patients.

Both icatibant and pdC1-INH significantly reduced attack duration compared with no treatment, however, icatibant was more effective but also more expensive. Treatment behaviours and suboptimal dosing of pdC1-INH may account for the differences, but further research is needed to define their role.